Prenetics Global (NASDAQ:PRE - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a note issued to investors on Saturday.
Prenetics Global Price Performance
Prenetics Global stock opened at $8.04 on Friday. The stock's 50 day moving average is $7.60 and its 200 day moving average is $5.85. The firm has a market cap of $98.03 million, a P/E ratio of -2.01 and a beta of 0.15. Prenetics Global has a one year low of $3.09 and a one year high of $11.99.
Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. The company had revenue of $17.31 million during the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. Equities analysts anticipate that Prenetics Global will post -3.3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Prenetics Global
A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 25.01% of the company's stock.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
